• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Arcutis Biotherapeutics, Inc. - Common stock (NQ:ARQT)

    19.76 +0.91 (+4.83%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Oct 1, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 3,342,184
    Open 18.90
    Bid (Size) 19.51 (2)
    Ask (Size) 19.93 (7)
    Prev. Close 18.85
    Today's Range 18.79 - 20.10
    52wk Range 8.030 - 19.36
    Shares Outstanding 50,241,789
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Arcutis Biotherapeutics to Host Virtual Investor Day and Report Third Quarter 2025 Financial Results on October 28, 2025
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    Arcutis To Present Multiple New ZORYVE® (roflumilast) Data Analyses at European Academy of Dermatology and Venereology Congress
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire

    Performance

    YTD
    +35.7%
    +35.7%
    1 Month
    +29.0%
    +29.0%
    3 Month
    +43.7%
    +43.7%
    6 Month
    +31.9%
    +31.9%
    1 Year
    +112.5%
    +112.5%

    More News

    Read More
    Allure Magazine Honors Arcutis’ ZORYVE® (roflumilast) with Prestigious Best of Beauty Breakthrough Award
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    Earnings Scheduled For August 6, 2025
    Via Benzinga
    Earnings Scheduled For May 6, 2025
    Via Benzinga
    ARCUTIS BIOTHERAPEUTICS INC (NASDAQ:ARQT) Combines Technical Strength with High Growth Momentum
    Via Chartmill
    Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Cream 0.3% to Expand Indication for Treatment of Plaque Psoriasis in Children Ages 2 to 5
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    Palvella Therapeutics Strengthens Leadership with Appointment of Accomplished Scientist and Biopharmaceutical Executive David W. Osborne, Ph.D. as Chief Innovation Officer
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    Top 5 Biotech Stocks With Strong Momentum
    Via Benzinga
    3 Biotech Catalysts Present Major Opportunity
    Via MarketBeat
    Arcutis Biotherapeutics Inc (NASDAQ:ARQT) Fits the Minervini Trend Template with Strong Growth Momentum
    Via Chartmill
    Arcutis (ARQT) Q2 Revenue Soars 164%
    Via The Motley Fool
    Arcutis Biotherapeutics Inc (NASDAQ:ARQT) Beats Q2 2025 Revenue Estimates and Posts Narrower Loss Than Expected
    Via Chartmill
    Arcutis Announces Second Quarter 2025 Financial Results and Provides Business Update
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    This Palantir Technologies Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
    Via Benzinga
    Arcutis’ ZORYVE® (roflumilast) Cream 0.15% Receives Strong Recommendation in American Academy of Dermatology Updated Guidelines for Adult Atopic Dermatitis
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    Arcutis Enrolls First Child in INTEGUMENT-INFANT Evaluating ZORYVE® (roflumilast) Cream 0.05% in Infants with Atopic Dermatitis
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    Arcutis Unveils Long-Term Efficacy, Safety For Zoryve Cream In Pediatric Patients With Atopic Dermatitis
    Via Benzinga
    Arcutis to Present New Long-Term Results of ZORYVE® (roflumilast) Cream at the 2025 Revolutionizing Atopic Dermatitis Conference
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    Analyst Expectations For Arcutis Biotherapeutics's Future
    Via Benzinga
    Arcutis’ ZORYVE® (roflumilast) Topical Foam 0.3% Approved by U.S. FDA for the Treatment of Plaque Psoriasis in Adults and Adolescents Ages 12 and Older
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    New Consensus Statements on Impact of Genital Psoriasis on Patients from Genital Psoriasis Wellness Consortium Published in Journal of the European Academy of Dermatology and Venereology Clinical Practice
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    Arcutis Announces Publication of Positive Data from ARRECTOR Trial Evaluating ZORYVE® (roflumilast) Foam 0.3% in Individuals with Psoriasis in Journal of American Medical Association Dermatology
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    Arcutis Announces First Quarter 2025 Financial Results and Provides Business Update
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    Would Mark Minervini consider ARCUTIS BIOTHERAPEUTICS INC (NASDAQ:ARQT) a top stock pick?
    Via Chartmill

    Frequently Asked Questions

    Is Arcutis Biotherapeutics, Inc. - Common stock publicly traded?
    Yes, Arcutis Biotherapeutics, Inc. - Common stock is publicly traded.
    What exchange does Arcutis Biotherapeutics, Inc. - Common stock trade on?
    Arcutis Biotherapeutics, Inc. - Common stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Arcutis Biotherapeutics, Inc. - Common stock?
    The ticker symbol for Arcutis Biotherapeutics, Inc. - Common stock is ARQT on the Nasdaq Stock Market
    What is the current price of Arcutis Biotherapeutics, Inc. - Common stock?
    The current price of Arcutis Biotherapeutics, Inc. - Common stock is 19.76
    When was Arcutis Biotherapeutics, Inc. - Common stock last traded?
    The last trade of Arcutis Biotherapeutics, Inc. - Common stock was at 10/01/25 04:00 PM ET
    What is the market capitalization of Arcutis Biotherapeutics, Inc. - Common stock?
    The market capitalization of Arcutis Biotherapeutics, Inc. - Common stock is 992.78M
    How many shares of Arcutis Biotherapeutics, Inc. - Common stock are outstanding?
    Arcutis Biotherapeutics, Inc. - Common stock has 993M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms Of Service.